Q3 Earnings Estimate for CorMedix Issued By Leerink Partnrs

CorMedix Inc. (NASDAQ:CRMD - Free Report) - Stock analysts at Leerink Partnrs lowered their Q3 2025 earnings per share estimates for CorMedix in a research note issued to investors on Tuesday, May 6th. Leerink Partnrs analyst R. Ruiz now expects that the company will post earnings per share of $0.13 for the quarter, down from their previous forecast of $0.16. Leerink Partnrs currently has a "Strong-Buy" rating on the stock. The consensus estimate for CorMedix's current full-year earnings is ($0.32) per share. Leerink Partnrs also issued estimates for CorMedix's FY2025 earnings at $0.68 EPS.

Several other research analysts have also weighed in on CRMD. Needham & Company LLC increased their target price on CorMedix from $12.00 to $15.00 and gave the stock a "buy" rating in a research report on Wednesday, May 7th. StockNews.com raised CorMedix from a "sell" rating to a "hold" rating in a research report on Tuesday, April 1st. D. Boral Capital reissued a "buy" rating and issued a $15.00 price objective on shares of CorMedix in a research report on Tuesday, May 6th. Leerink Partners began coverage on CorMedix in a research report on Friday, March 7th. They issued an "outperform" rating and a $18.00 price objective on the stock. Finally, Royal Bank of Canada reissued an "outperform" rating and issued a $12.00 price objective on shares of CorMedix in a research report on Wednesday, March 26th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Buy" and an average price target of $15.00.

CorMedix Stock Down 1.3%

Shares of CRMD stock traded down $0.15 during trading hours on Thursday, hitting $11.71. 591,134 shares of the company were exchanged, compared to its average volume of 1,136,046. The firm has a market cap of $794.23 million, a PE ratio of -14.46 and a beta of 1.54. The firm has a fifty day moving average of $8.76 and a 200 day moving average of $9.73. CorMedix has a 1 year low of $3.61 and a 1 year high of $13.85.

CorMedix (NASDAQ:CRMD - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported $0.30 earnings per share for the quarter, topping the consensus estimate of $0.25 by $0.05. The company had revenue of $39.08 million for the quarter, compared to analysts' expectations of $38.90 million. During the same quarter in the previous year, the company earned ($0.25) earnings per share.

Institutional Trading of CorMedix

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. increased its position in shares of CorMedix by 7.9% during the first quarter. Vanguard Group Inc. now owns 3,646,551 shares of the company's stock worth $22,463,000 after acquiring an additional 268,360 shares during the last quarter. Elliott Investment Management L.P. increased its position in shares of CorMedix by 85.1% during the fourth quarter. Elliott Investment Management L.P. now owns 2,870,632 shares of the company's stock worth $23,252,000 after acquiring an additional 1,320,109 shares during the last quarter. Geode Capital Management LLC increased its position in shares of CorMedix by 8.4% during the fourth quarter. Geode Capital Management LLC now owns 1,392,820 shares of the company's stock worth $11,284,000 after acquiring an additional 108,356 shares during the last quarter. Northern Trust Corp increased its position in shares of CorMedix by 14.4% during the fourth quarter. Northern Trust Corp now owns 511,565 shares of the company's stock worth $4,144,000 after acquiring an additional 64,243 shares during the last quarter. Finally, J. Goldman & Co LP increased its position in shares of CorMedix by 221.1% during the fourth quarter. J. Goldman & Co LP now owns 457,320 shares of the company's stock worth $3,704,000 after acquiring an additional 314,880 shares during the last quarter. 34.18% of the stock is owned by hedge funds and other institutional investors.

CorMedix Company Profile

CorMedix Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.